Roche will join Pieris Pharmaceuticals in an up-to-CHF 415 million ($409 million) cancer immunotherapy collaboration designed to develop new drug candidates based on Pieris’ Anticalin® technology platform against an undisclosed target.
Under its first partnered immune-oncology program, Pieris will discover, characterize and optimize Anticalin-based drug candidates. Pieris will then work with Roche to assess various drug formats against the target, and advance them through preclinical development.
{iframe}http://www.genengnews.com/gen-news-highlights/roche-inks-up-to-409m-cancer-immunotherapy-alliance-with-pieris/81252071/{/iframe}